Two Appili programs, ATI-1701 and ATI-1801, may be eligible for Priority Review Vouchers (PRVs) upon the renewal of certain US legislation. PRVs are transferable and recently sold for US$200M+, representing significant non-dilutive value. appilitherapeutics.com/pipel… $APLI $APLIF

Appili's Dr. Gelhaus represented Appili at the 2026 MCDC Annual Membership Meeting. As a member of MCDC (with US$7B+ awarded to date), Appili can actively pursue new funding opportunities aligned with DOD objectives. medcbrn.org/ #MCDC #biodefense $APLI $APLIF

@Appili and its partners secured US$75M in government contracts, demonstrating the strength of its non-dilutive funding model. This strategic approach provides capital to accelerate pipeline development without diluting shareholder value. $APLI $APLIF appilitherapeutics.com/

Millions suffer from tropical diseases with limited treatment options. The FDA PRV program incentivizes biotechs to develop treatments for underserved populations. PRVs are transferrable with sales often +$150M. #RareDiseaseDay $APLI $APLIF appilitherapeutics.com/pipel…

ATI 1801 is licensed from USAMMDA and supported by a robust clinical dossier, including a successful Phase 3 trial. At @Appili, we are pursuing funding from global organizations and partners to accelerate ATI 1801’s FDA development pathway. $APLI $APLIF appilitherapeutics.com/ati-1…

@Appili reports Q3 FY2026 results, highlighting strong momentum in government‑funded and commercial programs. -US$82M in pending funding proposals -New NIAID US$40M contract to advance VXV‑01 -LIKMEZ building US market adoption $APLI $APLIF appilitherapeutics.com/2026/… #funding

In 2025, Appili submitted multiple U.S. funding proposals representing up to US$90M. If awarded, the funds would support critical development activities across the portfolio. Awards from proposals are anticipated to be announced in Q1 2026. $APLI $APLIF appilitherapeutics.com/

Millions suffer from NTDs with limited treatment options. The FDA PRV program incentivizes biotechs to develop treatments for underserved populations. PRVs are transferable and highly valuable, with recent sales often exceeding $100 million! $APLI $APLIF appilitherapeutics.com/pipel…

@Appili reports financial and operational results for Q2 FY2026 - New @NIH NIAID funding award of up to US $40M - Multiple government proposals submitted, totalling up to US $90M $APLI $APLIF appilitherapeutics.com/2025/…

CEO, Don Cilla will represent Appili at the 2025 @BARDA Innovation Symposium on Nov 20 in DC! Excited to connect with leaders, share our advances, and build partnerships advancing medical countermeasures. drive.hhs.gov/innovation2025… $APLI $APLIF #BARDAInnovation #Biotech

A new WHO report reveals over a billion people are affected by NTDs. ATI-1801 represents our commitment to addressing cutaneous leishmaniasis and bridging treatment gaps. Join us, governments & NGOs in prioritizing solutions for communities. $APLI $APLIF who.int/news/item/22-10-2025…

Appili will attend BARDA Innovation Symposium on November 20 in Washington, DC, highlighting our role as a trusted U.S. government partner. This event convenes a network of government agencies, non dilutive funders, investors and partners. $APLI $APLIF appilitherapeutics.com/2025/…

ICYMI: Appili & Vitalex secured a US $40M NIAID contract to advance VXV-01, a first-in-class fungal vaccine. With no approved fungal vaccines for humans, VXV-01 aims to fill an urgent unmet need! #Biotech #Innovation #Appili $APLI $APLIF

Appili has secured a new NIAID contract worth up to US $40M — bringing our total government funding awards to US $74M, with US $97M more in pending applications. $APLI $APLIF #biotech #funding #innovation #Appili appilitherapeutics.com/2025/…

Appili announces US$40M NIAID funding award to advance fungal vaccine, VXV-01, in collaboration with @VitalexBioscien. VXV-01 is designed to address the urgent threat of invasive fungal infections, affecting millions of people each year. $APLI $APLIF appilitherapeutics.com/2025/…

#Appili is pleased to report that all matters from our AGSM have been approved. These approvals enable us to execute key strategies and advance our pipeline of infectious disease solutions. Stay in touch: info@appilitherapeutics.com $APLI $APLIF appilitherapeutics.com/2025/…

Appili submitted seven U.S. government funding proposals totaling US$137M. MCDC membership provides direct access to government stakeholders, industry partners, and DOD-aligned opportunities. $APLI $APLIF appilitherapeutics.com/2025/…

@Appili reports financial and operational results for Q1 FY2026. -Seven U.S. proposals submitted, totalling up to US $137M -US $3.3M PRMRP funding application to advance ATI-1701 to IND $APLI $APLIF appilitherapeutics.com/2025/…

Check out a new publication co-authored Dr. Gelhaus in Vaccine. The new manuscript showcases the preclinical efficacy of ATI‑1701, a novel live attenuated tularemia vaccine with strong potential as a biodefense countermeasure. appilitherapeutics.com/2025/… #infectiousdiseases

Last week, Appili CDO, Dr. Nabors joined leaders from government and biodefense at CWMD&MCDC Membership Meeting. MCDC plays a critical role in fostering public–private partnerships to accelerate development of safe medical countermeasures. $APLI $APLIF appilitherapeutics.com/about…